Development

At IGENOMIX, we work in all the development phases of diagnostic tests: from the original concept, undertaking clinical studies, producing and analyzing results, to their transfer to become products that can be commercialized. In the Products Development Department, we do not merely adapt already established procedures, but we innovate to provide our patients with the best services.

OBJECTIVES

  • Continually improving the procedures that are commercialized in the company.
  • Transforming the knowledge generated in research projects into diagnosis products and personalized diagnosis methods.
  • Using genomics to develop new simpler, more complete, more accessible and, in particular, more personalized diagnosis methods.
  • Providing solutions for the requirements with which professionals are faced.

Reproductive genetics product development

PRODUCTS ON THE MARKET

Today, we offer a series of innovative and exclusive services of great value to professionals in reproductive medicine, as a result of our R&D efforts.

ERA

Endometrial receptivity is the state in which the endometrium is ready for embryonic implantation to take place. This occurs in all menstrual cycles in fertile women at around day 21 of the cycle. Currently, the only study done on the endometrium is an ultrasound scan, and there is no analysis method available that helps doctors in their clinical practice.
Within the study of an infertile couple, the ERA test (Endometrial Receptivity Analysis) assesses the woman’s endometrial receptivity status from the molecular viewpoint as an important analysis of the uterine factor. This molecular tool allows us to diagnose whether the endometrium is receptive or not by analyzing the expression of a group of genes responsible for this function. To go about this, an endometrial biopsy must be done on day 21 of the menstrual cycle (the receptive phase) or on day LH+7, or after 5 days of progesterone in a substitute cycle.